MLchartDataset catalogue

anti-CD123/anti-CD16A bispecific antibody AFM28

Term · Oncology and biomedicine · MLC-T-ONC-010219

A human, tetravalent, bispecific immunoglobulin G1 (IgG1)-single chain variable fragment (scFv) fusion antibody targeting both the tumor-associated antigen (TAA) CD123 and the human low affinity immunoglobulin G (IgG) Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD123/CD16A bispecific antibody AFM28 simultaneously targets and binds to CD16A expressed on natural killer (NK) cells and macrophages, and to CD123 on CD123-expressing tumor cells, thereby selectively cross-linking CD123-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, induce antibody-dependent cellular cytotoxicity (ADCC), and eventually causes tumor cell lysis. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. CD16A is specifically expressed on the surface of NK cells and macrophages.

Table 1. Record
IdentifierMLC-T-ONC-010219
FieldOncology and biomedicine
Synonymsbispecific innate cell engager AFM28; ICE AFM28; bispecific antibody anti-CD123/anti-CD16A AFM28
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010219",
  "term": "anti-CD123/anti-CD16A bispecific antibody AFM28",
  "field": "Oncology and biomedicine",
  "definition": "A human, tetravalent, bispecific immunoglobulin G1 (IgG1)-single chain variable fragment (scFv) fusion antibody targeting both the tumor-associated antigen (TAA) CD123 and the human low affinity immunoglobulin G (IgG) Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD123/CD16A bispecific antibody AFM28 simultaneously targets and binds to CD16A expressed on natural killer (NK) cells and macrophages, and to CD123 on CD123-expressing tumor cells, thereby selectively cross-linking CD123-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, induce antibody-dependent cellular cytotoxicity (ADCC), and eventually causes tumor cell lysis. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. CD16A is specifically expressed on the surface of NK cells and macrophages.",
  "synonyms": [
    "bispecific innate cell engager AFM28",
    "ICE AFM28",
    "bispecific antibody anti-CD123/anti-CD16A AFM28"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd123-anti-cd16a-bispecific-antibody-afm28/"
}

Record 1,304 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.